Merrill puts Vertex at neutral

Vertex Pharmaceuticals Inc. was rated at neutral by Merrill Lynch analyst Hari Sambasivam on news of the Johnson & Johnson VX-950 deal covering non-U.S. jurisdictions including Europe, South America, Middle East, Africa and Australia. The deal reduces the risk to Vertex in those markets while providing additional manufacturing capabilities. Shares of the Cambridge, Mass.-based pharmaceutical company were up $4.68, or 14.61%, at $36.71 on volume of 15,111,702 shares versus the three-month running average of 1,682,130 shares. (Nasdaq: VRTX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.